US FDA transparency group urges expanded disclosures on pending NDAs
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration’s transparency task force has recommended a dramatic expansion in the amount and types of information the agency discloses about pending drug and biological applications1.